SLIGRL-NH2 TFA, also known as Protease-Activated Receptor-2 Activating Peptide TFA, is a Protease-Activated Receptor-2 (PAR-2) agonist [1].

SLIGRL-NH2 serves as an agonist for both PAR-2 and MrgprC11 [1]. It induces a relaxation that is inhibited by L-NAME, suggesting a nitric oxide-dependent mechanism. Importantly, SLIGRL-NH2 achieves a concentration-dependent relaxation with an EC50 of 10 µM in endothelium-free preparations when accompanied by perivascular adipose tissue (PVAT). Consequently, a concentration of 20 µM is selected for further experiments to assess the influence of inhibitors on ADRF release and activity. In endothelium-denuded aortic preparations, the peptide solely elicits this concentration-dependent relaxation in conjunction with PVAT [+PVAT, -ENDO (endothelium)] [2].